Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Equities research analysts at B. Riley issued their Q1 2024 EPS estimates for Kymera Therapeutics in a research note issued to investors on Friday, February 23rd. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.79) for the quarter. The consensus […]
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $56 00 at Piper Sandler theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Eagle Asset Management Inc. raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 2.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 209,117 shares of the biotechnology company’s stock after acquiring an additional 4,732 shares during the quarter. Eagle […]
Eagle Asset Management Inc. lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 2.3% in the 3rd quarter, Holdings Channel reports. The fund owned 209,117 shares of the biotechnology company’s stock after acquiring an additional 4,732 shares during the quarter. Eagle Asset Management Inc.’s holdings in Blueprint Medicines were worth $10,502,000 as […]
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) had its price objective upped by Stifel Nicolaus from $35.00 to $55.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 35.84% from the stock’s previous close. Other research analysts […]